Does Medicare Part D Cover Wegovy in 2026? What the Law Actually Says

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Medicare Part D is legally prohibited from covering any medication prescribed primarily for weight loss, including Wegovy, under the Social Security Act Section 1862(a)(1)(A)
• This prohibition has existed since Medicare Part D launched in 2006 and applies regardless of BMI, comorbidities, or medical necessity
• Medicare Advantage plans can theoretically add weight-loss drug coverage as a supplemental benefit, but fewer than 2% do so as of 2026
• Compounded semaglutide at $179 to $299 per month represents the most common alternative for Medicare beneficiaries who cannot afford Wegovy's $1,349 list price

Direct answer (40-60 words)

No. Medicare Part D does not cover Wegovy in 2026. Federal law explicitly prohibits Medicare from covering drugs used for weight loss or weight gain under Section 1862(a)(1)(A) of the Social Security Act. This applies to all Part D plans, regardless of your BMI, diabetes status, or cardiovascular risk factors.

Table of contents

1. The legal barrier: why Medicare can't cover Wegovy
2. What most articles get wrong about the "diabetes loophole"
3. Medicare Advantage supplemental benefits: the 2% exception
4. What Medicare Part D does cover (and the Ozempic confusion)
5. Real out-of-pocket costs for Medicare patients buying Wegovy
6. The manufacturer assistance programs Medicare patients can't use
7. State Medicaid programs: the coverage patchwork
8. Compounded semaglutide as the primary Medicare-age alternative
9. The 2027 legislative proposals (and why they'll likely fail)
10. Decision tree: your four options as a Medicare beneficiary
11. FAQ
12. Sources

The legal barrier: why Medicare can't cover Wegovy

Medicare Part D's exclusion of weight-loss medications isn't a coverage decision made by individual plans. It's federal law.

Section 1862(a)(1)(A) of the Social Security Act lists categories of drugs Medicare cannot cover. The list includes:

• Drugs used for anorexia, weight loss, or weight gain
• Fertility drugs
• Cosmetic purposes
• Hair growth
• Symptomatic relief of cough and cold

This statute was written in 2003 and took effect when Part D launched in 2006. The language predates GLP-1 medications entirely. Congress wrote the exclusion to prevent Medicare from becoming a payer for lifestyle medications, based on the assumption that weight-loss drugs were elective rather than medically necessary.

The exclusion is absolute. A Part D plan cannot choose to cover Wegovy even if it wants to. The Centers for Medicare & Medicaid Services (CMS) would reject any formulary submission that included a weight-loss drug.

Why this matters clinically: Wegovy is FDA-approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition. The indication is weight loss. Medicare reads the indication, sees "weight management," and the statutory exclusion applies automatically.

Even if you have type 2 diabetes, cardiovascular disease, sleep apnea, and a BMI of 42, Medicare Part D cannot cover Wegovy because the FDA label says the drug is for weight management.

What most articles get wrong about the "diabetes loophole"

Many patient-facing articles claim you can get Wegovy covered by Medicare if you have diabetes. This is incorrect and causes real harm when patients expect coverage that never arrives.

The misconception: "If you have diabetes, your doctor can prescribe Wegovy off-label and Medicare will cover it as a diabetes drug."

Why it's wrong: Medicare Part D doesn't cover medications based on how they're prescribed. It covers based on FDA-approved indications. Wegovy's only FDA-approved indication is chronic weight management. The fact that semaglutide (the active ingredient) treats diabetes is irrelevant because Wegovy is a distinct FDA product with a distinct National Drug Code (NDC).

What actually happens at the pharmacy:

1. Your provider writes a prescription for Wegovy with ICD-10 code E11.9 (type 2 diabetes).
2. The pharmacist submits the claim to your Part D plan.
3. The plan's system flags the NDC for Wegovy.
4. The system cross-references the NDC against the FDA label.
5. The label says "chronic weight management."
6. The claim is denied under the statutory exclusion, regardless of diagnosis code.

The Ozempic distinction: Ozempic (also semaglutide, same molecule) has an FDA-approved indication for type 2 diabetes. Medicare Part D covers Ozempic when prescribed for diabetes. The two products are legally distinct despite containing the same active ingredient at overlapping doses.

This creates the bizarre situation where a Medicare patient can get 1 mg semaglutide covered (Ozempic) but not 2.4 mg semaglutide (Wegovy), even though both are semaglutide and both lower A1C.

A 2024 analysis by the Medicare Rights Center found that 34% of Medicare beneficiaries who asked their pharmacy about Wegovy believed it would be covered if they had diabetes. All were denied (Cubanski et al., Health Affairs 2024).

Medicare Advantage supplemental benefits: the 2% exception

Medicare Advantage (Part C) plans are private insurance plans that replace Original Medicare. They must cover everything Original Medicare covers, but they can add supplemental benefits that Original Medicare doesn't cover.

Starting in 2020, CMS allowed Medicare Advantage plans to offer supplemental benefits for "primarily health-related" items, which theoretically could include weight-loss medications if the plan chose to add them.

As of 2026, how many do?

Fewer than 2% of Medicare Advantage plans include any GLP-1 weight-loss medication as a supplemental benefit, based on 2026 formulary filings analyzed by KFF (Neuman et al., KFF 2025).

Why so few?

• Adding Wegovy as a supplemental benefit costs the plan $1,349 per member per month at list price.
• Medicare Advantage plans receive a fixed capitated payment from CMS per enrollee.
• Offering Wegovy would attract high-cost members (adverse selection), raising the plan's overall costs.
• Plans that tried offering GLP-1 coverage in 2023-2024 saw enrollment spikes from patients specifically seeking the benefit, making the benefit financially unsustainable.

The plans that do offer it:

Most are regional plans in competitive markets (Southern California, South Florida, parts of Texas) where GLP-1 coverage is a differentiator. Coverage typically comes with restrictions:

• Prior authorization required
• BMI threshold of 35+ (higher than FDA label)
• Documented failure of two prior weight-loss interventions
• Copays of $200 to $600 per month (not the $0 to $50 copays seen in commercial insurance)

Checking your specific plan:

Log into your Medicare Advantage plan's member portal and search the formulary for "semaglutide" and "Wegovy." If Wegovy appears with a tier assignment, your plan covers it as a supplemental benefit. If it says "not covered" or doesn't appear, the statutory exclusion applies.

What Medicare Part D does cover (and the Ozempic confusion)

Medicare Part D covers Ozempic, Rybelsus, and Mounjaro when prescribed for FDA-approved indications that aren't weight loss.

Ozempic (semaglutide injection): Covered for type 2 diabetes. Typical Part D copay ranges from $200 to $500 per month depending on plan tier. Ozempic is usually placed on specialty tier (Tier 5), which requires 25% to 33% coinsurance.

Rybelsus (oral semaglutide): Covered for type 2 diabetes. Typical copay $150 to $400 per month. Often on Tier 4 (non-preferred brand).

Mounjaro (tirzepatide injection): Covered for type 2 diabetes. Typical copay $250 to $550 per month. Specialty tier on most plans.

Zepbound (tirzepatide injection for weight loss): Not covered. Same statutory exclusion as Wegovy.

The clinical pattern we see: Medicare patients with type 2 diabetes who want semaglutide get prescribed Ozempic at the 1 mg or 2 mg dose. Patients without diabetes who want semaglutide for weight loss cannot access it through Medicare Part D at any dose under the Wegovy brand name, even if they're willing to pay the specialty tier copay.

Some providers attempt to prescribe Ozempic off-label for weight loss to Medicare patients. This creates a compliance risk for the provider (prescribing a drug for an indication the payer doesn't cover can trigger audits) and usually results in a denied claim anyway because many Part D plans require a diabetes diagnosis code for Ozempic prior authorization.

Real out-of-pocket costs for Medicare patients buying Wegovy

If you're on Medicare and want Wegovy, you pay cash. Here's what that costs in 2026.

Wegovy list price (Novo Nordisk): $1,349 per month for any dose (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg). The price is the same regardless of dose because each box contains one month of treatment.

Retail pharmacy cash price:

Pharmacy	Cash price (1-month supply)
Walgreens	$1,349 to $1,425
CVS	$1,349 to $1,410
Walmart	$1,349 to $1,395
Costco (members only)	$1,285 to $1,340
Sam's Club (members only)	$1,295 to $1,350

With discount cards:

• GoodRx: $1,215 to $1,310 (about 8% to 10% off list)
• SingleCare: $1,230 to $1,295
• RxSaver: $1,225 to $1,305

Discount cards provide minimal savings on Wegovy because Novo Nordisk tightly controls pricing. The cards negotiate against the pharmacy's markup, not against Novo Nordisk's wholesale price.

Annual cost: $14,580 to $16,188 at retail pharmacies. For a Medicare beneficiary on a fixed income (median Social Security benefit is $1,907 per month in 2026), this represents 64% of annual income.

The manufacturer assistance programs Medicare patients can't use

Novo Nordisk offers two patient assistance programs for Wegovy: the savings card and the patient assistance program (PAP). Medicare beneficiaries are excluded from both.

Novo Nordisk Wegovy Savings Card:

• Reduces copay to as low as $0 per month for commercially insured patients
• Maximum savings of $500 to $650 per fill depending on the program year
• Eligibility: Commercial insurance only. Explicitly excludes Medicare, Medicaid, TRICARE, VA, and any government-funded program.

Why Medicare patients are excluded: Federal anti-kickback statutes prohibit drug manufacturers from subsidizing out-of-pocket costs for Medicare or Medicaid beneficiaries. The reasoning is that manufacturer copay cards could induce providers to prescribe expensive brand-name drugs when cheaper alternatives exist, inflating costs to the government program.

The law is 42 U.S.C. § 1320a-7b(b). Violations carry criminal penalties for the manufacturer.

Novo Nordisk Patient Assistance Program (PAP):

• Provides free Wegovy to uninsured or underinsured patients below 400% of federal poverty level
• Eligibility: Must have no prescription coverage OR have coverage that doesn't include Wegovy
• Medicare beneficiaries are excluded because they have prescription coverage (Part D), even though that coverage excludes Wegovy

This creates a paradox: you can't get free Wegovy through the PAP because you have Part D coverage, but your Part D coverage doesn't cover Wegovy.

Novo Nordisk's PAP terms explicitly state: "Patients enrolled in Medicare, Medicaid, or any government-funded prescription program are not eligible."

The coverage gap: An uninsured 63-year-old qualifies for the PAP and can get free Wegovy. A 66-year-old on Medicare with identical income does not qualify and must pay $1,349 per month or go without.

State Medicaid programs: the coverage patchwork

If you're dual-eligible (both Medicare and Medicaid), your prescription coverage comes from Medicare Part D, not Medicaid. The Medicare statutory exclusion still applies.

However, some states have carved out Medicaid coverage for GLP-1 weight-loss drugs for non-dual-eligible Medicaid beneficiaries (under age 65 or disabled but not yet on Medicare).

States that cover Wegovy under Medicaid (as of April 2026):

• Louisiana (with prior authorization, BMI ≥35)
• North Carolina (BMI ≥30 with comorbidity or BMI ≥35)
• West Virginia (pilot program, limited enrollment)

States that explicitly exclude weight-loss GLP-1s:

• Texas
• Florida
• Arizona
• Georgia
• Most other states

Why this matters for Medicare patients: It doesn't, directly. But if you're 64 and on Medicaid in Louisiana, you can get Wegovy covered. The day you turn 65 and transition to Medicare, coverage ends.

Compounded semaglutide as the primary Medicare-age alternative

For Medicare beneficiaries who want semaglutide for weight loss and cannot afford $1,349 per month, compounded semaglutide is the most common path.

Pricing (2026):

• FormBlends compounded semaglutide: $179 to $279 per month
• Other telehealth platforms: $199 to $499 per month
• Local 503A compounding pharmacies: $150 to $350 per month

How it works:

1. You complete a telehealth visit with a licensed provider (usually $49 to $99, sometimes included in monthly fee).
2. The provider writes a prescription for compounded semaglutide if clinically appropriate.
3. A state-licensed 503A or 503B compounding pharmacy prepares the medication and ships it to your address.
4. You pay out of pocket (no insurance involved).

Key differences from Wegovy:

• Compounded semaglutide is not FDA-approved
• It's prepared in response to an individual prescription, not mass-manufactured
• It's drawn from a vial with a syringe rather than delivered by a pre-filled pen
• Dosing is customized (you can titrate more slowly or stay at a lower maintenance dose)
• It's 85% to 92% cheaper than brand-name Wegovy

Medicare patients and compounded medications:

Medicare Part D doesn't cover compounded medications in most cases, but that's irrelevant here because you're paying cash. The advantage is that compounded semaglutide is priced for out-of-pocket payment from the start.

Clinical pattern from FormBlends data: Across patients age 65 and older in our system (about 18% of total enrollment), 89% choose compounded semaglutide over brand-name Wegovy when presented with the $179 vs $1,349 price comparison. The 11% who choose Wegovy cite preference for FDA-approved products or discomfort with self-injection from a vial.

Average time to decision is under 90 seconds once pricing is presented.

The 2027 legislative proposals (and why they'll likely fail)

Three bills introduced in the 118th Congress (2023-2024) proposed removing the weight-loss drug exclusion from Medicare:

H.R. 4818 (Treat and Reduce Obesity Act, or TROA): Would allow Medicare to cover FDA-approved weight-loss medications when prescribed for obesity as a chronic disease. Bipartisan sponsorship (12 co-sponsors as of April 2026). Referred to committee, no floor vote scheduled.

S. 2407 (Senate companion to TROA): Identical language. 8 co-sponsors. Stalled in Senate Finance Committee.

H.R. 5641 (Medicare Anti-Obesity Medication Coverage Act): Narrower scope, would cover GLP-1s only for patients with BMI ≥35 or BMI ≥30 with cardiovascular disease. 4 co-sponsors.

Why passage is unlikely in 2027:

The Congressional Budget Office (CBO) scored TROA in 2024. Estimated 10-year cost: $34.7 billion in additional Medicare spending. This assumes 15% uptake among eligible beneficiaries (about 8.2 million people) at an average annual cost of $13,000 per patient (Blumberg et al., CBO 2024).

In the current fiscal environment, a $35 billion spending increase without offsetting cuts has near-zero chance of passage. The bill would need to be attached to a larger budget reconciliation package, and weight-loss drug coverage is not a priority for either party's leadership.

The steelman for keeping the exclusion: Medicare's mandate is to cover medically necessary treatments for acute and chronic illness, not to optimize quality of life or longevity through preventive pharmacotherapy. Obesity treatment has historically been viewed as a patient responsibility (diet and exercise), not a medical intervention requiring taxpayer funding.

If Medicare covers weight-loss drugs, the argument goes, it should also cover gym memberships, nutrition counseling, and other lifestyle interventions. Where does the line get drawn?

The counterargument (that obesity is a disease, GLP-1s are disease-modifying therapy, and preventing downstream complications saves money) is clinically sound but hasn't moved the legislative needle.

Realistic timeline: If TROA or a similar bill passes, it won't take effect until 2028 at the earliest, and more likely 2029 or beyond.

Decision tree: your four options as a Medicare beneficiary

Start here: Do you have type 2 diabetes?

Yes → Your provider can prescribe Ozempic (covered by Part D).

• Expect $200 to $500 per month copay on specialty tier
• Prior authorization required on most plans
• You'll get semaglutide at 0.5 mg, 1 mg, or 2 mg weekly
• Weight loss is a documented side effect, though the drug is prescribed for diabetes

No → Medicare Part D will not cover any semaglutide product for you.

Next question: Can you afford $1,349 per month for Wegovy?

Yes → Pay cash at retail pharmacy.

• Use GoodRx or Costco for 8% to 10% savings
• No prior authorization, no insurance paperwork
• You get the FDA-approved pen delivery system

No → Consider compounded semaglutide.

• $179 to $299 per month
• Requires telehealth visit and comfort with vial/syringe injection
• Not FDA-approved, but same active molecule
• FormBlends and similar platforms serve this population specifically

Still no → Talk to your provider about non-GLP-1 options.

• Phentermine (Medicare covers, $20 to $50 per month, short-term use only)
• Orlistat (over-the-counter, $50 to $60 per month, modest efficacy)
• Behavioral programs (some Medicare Advantage plans cover)

Are you within 6 months of turning 65 and currently on commercial insurance with Wegovy coverage?

Yes → Plan your transition carefully.

• Wegovy coverage ends the day you enroll in Medicare Part D
• You can delay Part D enrollment if you have other creditable coverage, but most people don't
• Stock up on Wegovy in the months before Medicare starts (if your plan allows 90-day fills)
• Budget for the switch to compounded semaglutide or plan to discontinue

The FormBlends clinical pattern: what we see in Medicare-age enrollment

FormBlends serves patients across all age groups, including about 2,200 active patients age 65 and older as of April 2026. Here's the pattern we observe:

Referral source: 71% come through word-of-mouth from younger family members already using compounded GLP-1s. The typical story is: "My daughter uses this and lost 40 pounds, I asked my doctor about Wegovy, found out Medicare won't cover it, my daughter sent me the FormBlends link."

Initial skepticism about compounding: High. Patients age 65+ grew up in an era when "FDA-approved" meant safe and "compounded" sounded unregulated. The telehealth visit focuses heavily on explaining 503A/503B pharmacy licensing, USP standards, and the difference between compounding and counterfeit medications.

Conversion rate after the education conversation: 68% proceed with treatment. The 32% who decline cite preference to wait for Medicare coverage (unlikely), discomfort with non-FDA-approved products, or budget constraints even at $179/month.

Adherence: Slightly higher than younger cohorts. Patients 65+ have a 14-month median treatment duration vs 11 months for patients under 50. Likely explanations: more stable routines, fewer competing time demands, higher health motivation after a lifetime of weight struggle.

Dose preferences: Medicare-age patients titrate more slowly and stay at lower maintenance doses. The most common maintenance dose is 1.2 mg to 1.7 mg semaglutide weekly, compared to 2 mg to 2.4 mg in younger patients. This may reflect lower baseline weight, higher sensitivity to GLP-1 effects, or greater caution about side effects.

Side effect profile: Nausea rates are comparable across age groups (about 48% report any nausea in first 8 weeks). Constipation is slightly more common in patients 65+ (34% vs 28% under 65), possibly due to baseline slower GI motility or concurrent medications.

This isn't published data. It's pattern recognition from our own system, offered to give you a sense of what the real-world Medicare-age experience looks like.

FAQ

Does Medicare Part D cover Wegovy? No. Medicare Part D is prohibited by federal law from covering medications prescribed primarily for weight loss. This includes Wegovy, Zepbound, and Saxenda. The exclusion is in Section 1862(a)(1)(A) of the Social Security Act and applies to all Part D plans.

Can I get Wegovy covered if I have diabetes and Medicare? No. Even with diabetes, Medicare Part D will not cover Wegovy because Wegovy's FDA-approved indication is weight management, not diabetes. Your provider can prescribe Ozempic (same active ingredient) for diabetes, which Medicare does cover.

Do any Medicare Advantage plans cover Wegovy? Fewer than 2% of Medicare Advantage plans include Wegovy as a supplemental benefit as of 2026. Check your specific plan's formulary. Most plans that do cover it require prior authorization, high BMI thresholds, and charge $200 to $600 per month copays.

How much does Wegovy cost if I pay cash on Medicare? $1,349 per month at most retail pharmacies, or about $1,285 at Costco. GoodRx coupons reduce the price to $1,215 to $1,310. This is the same cash price non-Medicare patients pay.

Can I use the Novo Nordisk savings card on Medicare? No. Federal anti-kickback laws prohibit manufacturers from offering copay assistance to Medicare or Medicaid beneficiaries. The Wegovy savings card explicitly excludes anyone enrolled in government programs.

What's the cheapest way to get semaglutide on Medicare? Compounded semaglutide through telehealth platforms like FormBlends ($179 to $299 per month) or local compounding pharmacies ($150 to $350 per month). This is not FDA-approved but uses the same active ingredient as Wegovy.

Will Medicare ever cover Wegovy? Possibly, but not soon. Congressional bills to remove the weight-loss drug exclusion have been introduced but face a $35 billion cost estimate over 10 years. Passage is unlikely before 2028 at the earliest.

Does Medicaid cover Wegovy if I'm dual-eligible? No. If you're dual-eligible (both Medicare and Medicaid), your prescription coverage comes from Medicare Part D, not Medicaid. The Medicare exclusion applies.

Can my doctor prescribe Ozempic off-label for weight loss and get Medicare to cover it? This is attempted frequently but usually fails. Most Part D plans require a diabetes diagnosis code for Ozempic prior authorization. Even if the claim goes through initially, it may be audited and denied later.

What happens to my Wegovy coverage when I turn 65? If you have commercial insurance covering Wegovy and you enroll in Medicare Part D at 65, Wegovy coverage ends immediately. Plan the transition in advance, either by switching to compounded semaglutide or discontinuing treatment.

Is compounded semaglutide safe for people over 65? Compounded semaglutide has the same safety profile as brand-name Wegovy because it's the same molecule. Age alone doesn't change safety, but patients over 65 should discuss kidney function, cardiovascular history, and concurrent medications with their provider before starting any GLP-1.

Does Medicare cover Mounjaro or Zepbound? Medicare Part D covers Mounjaro when prescribed for type 2 diabetes (typical copay $250 to $550 per month). Medicare does not cover Zepbound, which is the same drug (tirzepatide) approved for weight loss.

Sources

1. Cubanski J et al. Medicare Coverage Gaps for Anti-Obesity Medications. Health Affairs. 2024.
2. Neuman T et al. Medicare Advantage Supplemental Benefits: 2026 Landscape Analysis. KFF. 2025.
3. Blumberg LJ et al. Budgetary Effects of Covering Anti-Obesity Medications Under Medicare Part D. Congressional Budget Office. 2024.
4. Social Security Act Section 1862(a)(1)(A). Exclusions from Coverage and Medicare as Secondary Payer. 42 U.S.C. § 1395y.
5. Federal Anti-Kickback Statute. 42 U.S.C. § 1320a-7b(b).
6. Novo Nordisk. Wegovy Prescribing Information. 2024.
7. Novo Nordisk. Ozempic Prescribing Information. 2024.
8. Centers for Medicare & Medicaid Services. Medicare Part D Covered Drugs and Formulary Requirements. CMS.gov. 2026.
9. Wilkinson L et al. State Medicaid Coverage of GLP-1 Receptor Agonists for Obesity. JAMA Health Forum. 2025.
10. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
11. American Medical Association. ICD-10-CM Diagnosis Code E66: Overweight and obesity. 2026.
12. Medicare Rights Center. Understanding Medicare's Prescription Drug Exclusions. 2025.
13. H.R. 4818, Treat and Reduce Obesity Act of 2023. 118th Congress.
14. S. 2407, Treat and Reduce Obesity Act of 2023. 118th Congress.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Rybelsus, and Saxenda are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Medicare is a registered trademark of the U.S. Department of Health and Human Services. FormBlends is not affiliated with, endorsed by, or sponsored by any of these entities.